Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin b for antifungal prophylaxis in patients with acute myeloid leukemia

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2596-2602

  Annino, Luciana ^a   Chierichini, Anna ^a   Anaclerico, Barbara ^a   Finolezzi, Erica ^a   Norata, Marianna ^a   Cortese, Stefania ^a   Cassett, Maria Iris ^a,b   Fallani, Stefania ^b   Novelli, Andrea ^b   Girmenia, Corrado ^c  

^a SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HUMAN; HYPOKALEMIA; INFUSION RELATED REACTION; LOW BACK PAIN; MALE; NEPHROTOXICITY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; TREATMENT RESPONSE;

ADULT; AGED; AMPHOTERICIN B; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84877857359     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00155-13     Document Type: Article

References (36)

1. Anderlini P, Luna M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Estey EH. 1996. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia 10:600-608.
2. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A. 2006. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 91:1068-1075.
3. Pagano L, Caira M, Picardi M, Candoni A, Melillo L, Fianchi L, Offidani M, Nosari A. 2007. Invasive aspergillosis in patients with acute leukemia: Update on morbidity and mortality-SEIFEM-C report. Clin. Infect. Dis. 44:1524-1525.
4. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A. 2010. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica 95:644-650.
5. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
6. Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA. 2010. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): A 6 year experience of the Cologne AML cohort. J. Antimicrob. Chemother. 65:1466-1471.
7. Hahn J, Stifel F, Reichle A, Holler E, Andreesen R. 2011. Clinical experience with posaconazole prophylaxis-a retrospective analysis in a haematological unit. Mycoses 54(Suppl 1):12-16.
8. Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S, Trisolini SM, Matturro A, Loglisci G, Latagliata R, Breccia M, Meloni G, Alimena G, Foà R, Micozzi A. 2012. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: A single center real life experience. Haematologica 97:560-567.
9. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M. 2007. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J. Clin. Oncol. 25:5471-5489.
10. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
11. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, Gachot B, Heinz WJ, Lass-Flörl C, Ribaud P, Thiebaut A, Cordonnier C, Third European Conference on Infections in Leukemia. 2011. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 3-2009 update. Bone Marrow Transplant. 46:709-718.
12. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ. 2009. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113-122.
13. Girmenia C. 2009. New generation azole antifungals in clinical investigation. Expert Opin. Invest. Drugs 18:1279-1295.
14. Muller C, Arndt M, Queckenberg C, Cornely OA, Theisohn M. 2006. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 49(Suppl 1):17-22.
15. Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard JP, Bougnoux ME, Lecuit M, Jullien V, Lortholary O. 2009. Therapeutic drug monitoring of posaconazole: A monocentric study with 54 adults. Antimicrob. Agents Chemother. 53:5224-5229.
16. Thompson GR, III, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS, II. 2009. Posaconazole therapeutic drug monitoring: A reference laboratory experience. Antimicrob. Agents Chemother. 53:2223-2224.
17. Sanz M, Burnett A, Lo-Coco F, Löwenberg B. 2009. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr. Opin. Oncol. 21: 594-600.
18. Tollemar J, Ringdén O, Andersson S, Sundberg B, Ljungman P, Tydén G. 1993. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 12:577-582.
19. Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, Mufti GJ. 1999. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 23:163-168.
20. Uhlenbrock S, Zimmermann M, Fegeler W, Jürgens H, Ritter J. 2001. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: Interim analysis of a prospective study. Mycoses 44:455-463.
21. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. 2003. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97:450-456.
22. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, Blau IW. 2006. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: Results from a randomized, single-center trial. Ann. Oncol. 17:1306-1312.
23. Roman E, Osunkwo I, Militano O, Cooney E, van de Ven C, Cairo MS. 2008. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr. Blood Cancer 50:325-330.
24. Bochennek K, Tramsen L, Schedler N, Becker M, Klingebiel T, Groll AH, Lehrnbecher T. 2011. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. Clin. Microbiol. Infect. 17:1868-1874.
25. Mehta P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C, Davies S. 2006. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study. Biol. Blood Marrow Transplant. 12:235-240.
26. El-Cheikh J, Faucher C, Fürst S, Duran S, Berger P, Vey N, Stoppa AM, Bouabdallah R, Gastaut JA, Viens P, Blaise D, Mohty M. 2007. Highdose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 39:301-306.
27. Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, Monchecourt F, Mahi L, Ribaud P. 2008. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME study. Int. J. Antimicrob. Agents 31:135-141.
28. Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. 2009. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients. Antimicrob. Agents Chemother. 53:3664-3674.
29. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T, EORTC/Leukemia Group GIMEMA. 2005. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study. Blood 106:27-34.
30. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T. 2009. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. J. Clin. Oncol. 27: 5397-5403.
31. Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L, Rizzoli V, Borlenghi E, Gaidano G, Magro D, Torelli G, Muus P, Venditti A, Cacciola E, Lauria F, Vignetti M, de Witte T. 2010. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC andGIMEMAleukaemia groups (AML-19). Br. J. Haematol. 149: 376-382.
32. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F, Italian Cooperative Group GIMEMA. 2010. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group. Blood 116:3171-3179.
33. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin. Infect. Dis. 34:7-14.
34. Adler-Moore JP, Olsen JA, Proffitt RT. 2004. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J. Antimicrob. Chemother. 54:1096-1102.
35. Lewis RE, Albert ND, Kontoyiannis DP. 2008. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 52:4178-4180.
36. Smith PJ, Olson JA, Constable D, Schwartz J, Proffitt RT, Adler-Moore JP. 2007. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J. Antimicrob. Chemother. 59:941-951.